It is common in medicine to titrate therapy according to target ranges of objectively measured parameters. Objective measurement of motor function is available for Parkinson’s Disease (PD), making it possible to optimise therapy and clinical outcomes. In this study, an accelerometry based measurement and predefined target ranges were used to assess motor function in a Northern Tasmania PD cohort managed by a Movement Disorder clinic. Approximately 40% (n = 103) of the total PD population participated in this study and motor scores were within target in 22%. In the 78% above target, changes in oral therapy were recommended in 74%, Advanced Therapy in 12% and treatment was contraindicated in 9%. Following changes in oral therapy, there was a further objective measurement and clinical consultation to establish whether scores had reached target range: if so subjects left the study, otherwise further changes of therapy were recommended (unless contraindications were present). Seventy-seven cases completed the study, with 48% achieving target (including 22% at outset), Advanced Therapy recommended in 19% and contraindications preventing any change in therapy in 17%. In the 43% of cases in whom oral therapy was changed, total UPDRS improved significantly (effect size = 8) as did the PDQ39 in cases reaching target. NMS Quest and MOCA scores also improved significantly. This study shows that many people in a representative cohort of PD would benefit from objective assessment and treatment of their PD features against a target.

在医学中，通常根据客观测量参数的目标范围来滴定治疗。运动功能的客观测量可用于帕金森氏病（PD），从而有可能优化治疗和临床结果。在这项研究中，基于加速度计的测量和预定义的目标范围被用于评估运动失调诊所管理的北塔斯马尼亚州PD队列的运动功能。约40％（n = 103）的总PD人群参加了这项研究，运动评分在目标范围内的比例为22％。在高于目标的78％中，建议进行口服治疗的改变为74％，建议进行高级治疗的为12％，禁忌治疗为9％。改变口服疗法后，将进行进一步的客观测量和临床咨询，以确定分数是否已达到目标范围：如果是，则受试者退出研究，否则建议进一步改变疗法（除非存在禁忌症）。77例患者完成了研究，其中48％的患者达到了目标（包括22％的患者开始接受治疗），推荐的高级疗法为19％，而禁忌症则阻止了治疗的任何改变（17％）。在43％的患者改变了口服疗法的情况下，在达到目标的情况下，总的UPDRS显着改善（效果量= 8），与PDQ39一样。NMS Quest和MOCA分数也显着提高。这项研究表明，具有代表性的PD人群中的许多人都将从客观评估和针对目标的PD功能治疗中受益。